Cargando…
Hyperthermia as a Potential Cornerstone of Effective Multimodality Treatment with Radiotherapy, Cisplatin and PARP Inhibitor in IDH1-Mutated Cancer Cells
SIMPLE SUMMARY: Mutations in the isocitrate dehydrogenases 1 and 2 are causal in the development and progression of high-grade chondrosarcoma, high-grade glioma and intrahepatic cholangiocarcinoma. Due to the lack of effective treatment options, these aggressive types of cancer have a dismal outcome...
Autores principales: | Khurshed, Mohammed, Prades-Sagarra, Elia, Saleh, Sarah, Sminia, Peter, Wilmink, Johanna W., Molenaar, Remco J., Crezee, Hans, van Noorden, Cornelis J. F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777513/ https://www.ncbi.nlm.nih.gov/pubmed/36551714 http://dx.doi.org/10.3390/cancers14246228 |
Ejemplares similares
-
IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
por: Khurshed, Mohammed, et al.
Publicado: (2018) -
In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma
por: Khurshed, Mohammed, et al.
Publicado: (2017) -
Wild-type and mutated IDH1/2 enzymes and therapy responses
por: Molenaar, Remco J., et al.
Publicado: (2018) -
Correction: Wild-type and mutated IDH1/2 enzymes and therapy responses
por: Molenaar, Remco J., et al.
Publicado: (2018) -
A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors
por: Khurshed, Mohammed, et al.
Publicado: (2021)